Clinician Bias and Opioid Stigma in Sickle Cell Disease Care

A recent study from the University of Chicago Medicine has revealed significant clinician bias against patients with sickle cell disease, particularly in the context of opioid treatment. The research, published in *JAMA Network Open*, analyzed nearly 40,000 clinician notes from 18,326 adult patients, highlighting that sickle cell patients are more likely to be labeled with negative descriptors such as "aggressive," "angry," and "noncompliant." These negative labels were found in 15% of notes for sickle cell patients, compared to 14% for patients with opioid use disorder and only 7% for Black patients without sickle cell disease.

UsNews and World ReportClinician Bias Linked to Opioid Stigma in Sickle Cell Care

The study indicates that the stigma surrounding opioid use is a primary driver of this bias, rather than race or chronic pain alone. Monica Peek, a primary care physician and health justice professor at UChicago Medicine, emphasized that many sickle cell patients, who are predominantly Black, are unfairly stereotyped as "drug-seekers." This stigma can lead to diminished empathy from healthcare providers and misremembering of critical health details, ultimately affecting the quality of care these patients receive.

Clinician Bias Linked to Opioid Stigma in Sickle Cell Care

In response to these findings, UChicago Medicine has initiated an anti-bias curriculum aimed at educating healthcare providers about the implications of their language and attitudes. The program employs roleplay and data-driven approaches to illustrate how biased notes can harm patient outcomes. Dr. Austin Wesevich, a hematologist involved in the study, noted that the curriculum has already been delivered to 70 residents and has garnered interest from other academic institutions. Early data suggests that this intervention may be effective in improving care quality for sickle cell patients.

Clinician Bias Linked to Opioid Stigma in Sickle Cell Care

The implications of this study extend beyond individual patient care. The persistent bias against sickle cell patients reflects broader societal issues regarding race and healthcare. As Peek pointed out, the intersection of various social identities can complicate the discrimination patients face, making it difficult to identify the root causes of bias in clinical settings.

Clinician Bias Linked to Opioid Stigma in Sickle Cell Care

• “Unfortunately, this contemporary media portrayal is all too relevant,” — Dr. Austin Wesevich, Hematology and Oncology Specialist, UChicago Medicine

UsNews and World Report

• “A patient with sickle cell disease who experiences daily pain and who happens to be Black and asking for opioid treatment deserves no less trust than any other patient.” — Dr. Austin Wesevich, Hematology and Oncology Specialist, UChicago Medicine

Clinician Bias Linked to Opioid Stigma in Sickle Cell Care

• “We need effective anti-bias interventions to improve care for patients with sickle cell disease, and this deeper understanding is a step in the right direction,” — Dr. Austin Wesevich, Hematology and Oncology Specialist, UChicago Medicine

Clinician Bias Linked to Opioid Stigma in Sickle Cell Care

The findings from the University of Chicago Medicine underscore the urgent need for systemic changes in how sickle cell disease is treated within healthcare settings. By addressing clinician bias and implementing educational interventions, there is potential for improved patient outcomes and a more equitable healthcare environment for those affected by this chronic condition.

Clinician Bias Linked to Opioid Stigma in Sickle Cell Care